

Applying Glycobiology To Develop Novel Medicines
About
IHP Therapeutics is applying Glycobiology to develop novel medicines. Glycobiology is an emerging field of research and drug development, with potential for treating multiple diseases.
IHP compounds are novel small molecule glycan therapeutics that inhibit selectin and complement activity. IHP’s lead compound, IHP-102, is a dual P-selectin and complement inhibitor, which targets diseases in hematology and oncology. IHP-102 has potential as a prodromal rescue therapeutic for sickle cell disease patients in vaso-occlusive crisis. This would address a critical treatment gap and empower patients in home or outpatient settings. In addition, IHP-102 is also using a targeted, biomarker driven approach to treat solid tumors, based on established role of P-selectin & complement in certain cancers. Beyond, IHP-102, IHP is utilizing its considerable expertise in glycobiology to create novel, second generation glycans.
Mission
To pioneer the development of novel glyco-medicines
Our Team
Rinko Ghosh, MS, MBA
President and CEO
Gabriel Njikang, PhD
Director of CMC
Jocelyn Jackson
CFO
John Paderi, PhD
Chief Science Officer
Peggy McLaughlin
VP of Clinical Operations
Kate Stuart, PhD
VP of Program Management
Robert Van Gorp
VP of Strategic Sourcing
Board of Directors
Rinko Ghosh, MS, MBA
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
Clinical and Scientific Advisors
Elaine Allen, PhD; University of California San Francisco
Eric Collisson, MD; University of California San Francisco
Robert Linhardt, PhD; Rensselaer Polytechnic Institute
John Repine, MD; University of Colorado Anschutz Medical Campus
Eric Schmidt, MD; University of Colorado Denver
Ethan Weiss, MD; University of California San Francisco
Our Team
Nathan Bachtell, MD
CMO
Gabriel Njikang, PhD
Director of CMC
Rinko Ghosh, MS, MBA
President and CEO
John Paderi, PhD
Chief Science Officer
Jocelyn Jackson
CFO
Kate Stuart, PhD
VP of Program Management
Peggy McLaughlin
VP of Clinical Operations
Robert Van Gorp
VP of Strategic Sourcing
Board of Directors
Rinko Ghosh, MS, MBA
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
Clinical and Scientific Advisors

Science
IHP Therapeutics is building on nearly a century of clinical and basic science research with glycan-based compounds to create the next generation of glyco-medicines to treat a broad spectrum of diseases, including those involving immune regulation and inflammatory processes.
Pipeline
